Xinnate AB, a biotech company developing therapies based on a pioneering immune-modulating peptides technology, targets dysfunctional healing, including treatment of the genetic disorder Epidermolysis Bullosa, is pleased to present clinical study results at the ongoing 2024 Annual Meeting of the European Society for Dermatological Research (ESDR).
The ESDR 2024 annual meeting, taking place in Lisbon, Portugal from September 4-7, is a major four-day event, with international attendance from over 1000 skin scientists. ESDR will feature a presentation titled “Randomized Controlled Trial of TCP-25 Gel: Dual-Action for Bacteria and Inflammation Control in Epidermal Wounds.” This work was generated in Xinnate´s initial phase I study, part I, which included healthy volunteers with induced blister wounds, and will be presented by Professor Artur Schmidtchen, Professor of Dermatology at Lund University.
Key findings from the study demonstrate that TCP-25 gel not only significantly reduces bacterial levels in and around wounds but also selectively preserves beneficial commensal bacteria. Additionally, the gel was found to downregulate key inflammatory proteins and cytokines, resulting in reduced wound exudation and preventing excess protein leakage.
-This is the first study to explore the effects of TCP-25 gel in human epidermal wounds, and the results are very promising for the further clinical development of TCP-25 for treatment of Epidermolysis Bullosa wounds, said Professor Schmidtchen.